NCT03475186

Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (actual)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive tests throughout the duration of the study.

Detailed description

This is a pilot study of an oral drug Ramipril to prevent cognitive decline in glioblastoma patients receiving partial brain radiation and concurrent and adjuvant temozolomide . Ramipril will be titrated to the highest tolerable dose during chemoradiation (2.5-5 mg). Once this dose is determined, the patient will continue at this dose for 4 months after the completion of chemoradiation. Patients will be followed until 5 months post chemoradiation for compliance, toxicity, cognitive decline and participant reported outcomes (PRO).

Conditions

• Glioblastoma
• Radiotherapy; Complications
• Cognitive Decline
• Chemoradiation

Interventions

Type	Name	Description
DRUG	Ramipril	2.5 - 5 mg oral, 1x daily for 22 weeks

Timeline

• Start date: 2019-03-25
• Primary completion: 2025-03-25
• Completion: 2025-03-25
• First posted: 2018-03-23
• Last updated: 2026-03-13
• Results posted: 2026-03-13

Locations

423 sites across 2 countries: United States, Guam

Regulatory

• FDA-regulated drug study